Corcept Therapeutics, IncRedwood City, California, United States
Disclosure information not submitted.
MON-516 - Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-control Type 2 Diabetes: Results From two Large, Prospective Studies
Monday, June 15, 20269:00 AM - 2:00 PM CT